Pharmaceutical Executive Daily: Neurocrine Biosciences Agrees to Acquire Soleno Therapeutics

Key Takeaways

• Neurocrine pays $2.9B for Soleno, 34% premium.
• Vykat XR adds $190M 2025 revenue, immediate accretion.
• Deal gives Neurocrine first metabolic disease commercial platform.
• BioNTech closes Singapore plant, $1.24B loss catalyst.
• Facility shutdown impacts ~85 employees, reflects mRNA demand drop.

Pulse Analysis

Neurocrine’s purchase of Soleno marks a decisive entry into the metabolic disease arena, a market projected to exceed $100 billion globally by 2030. By securing Vykat XR, the only FDA‑approved therapy for hyperphagia in Prader‑Willi syndrome, Neurocrine instantly adds a revenue stream that contributed $190 million last year and promises immediate earnings accretion. The premium paid reflects confidence in the drug’s niche positioning and the broader strategic aim to diversify beyond its neuroscience and rare‑disease core, potentially smoothing earnings volatility and attracting investors seeking multi‑segment exposure.

BioNTech’s decision to shutter its Singapore manufacturing hub illustrates the rapid contraction of the post‑pandemic mRNA vaccine market. After a €1.14 billion ($1.24 billion) net loss in 2025 and a projected 25% revenue dip in 2026, the company is reallocating capital toward oncology pipelines and non‑mRNA therapeutics, where growth prospects remain robust. The closure will affect roughly 85 employees but also signals to the industry that large‑scale mRNA capacity may become a surplus asset, prompting other firms to reassess regional production footprints and explore contract‑manufacturing alternatives.

Meanwhile, specialty‑drug manufacturers are confronting increasingly sophisticated payer designs that threaten patient access and profit margins. Two complementary tactics—exception pathways that bypass restrictive formularies and in‑benefit optimization that maximizes assistance within plan rules—are emerging as best practices. Companies that master both approaches can preserve adherence, limit out‑of‑pocket burdens, and safeguard commercial performance, a lesson that resonates for Neurocrine as it integrates a high‑cost rare‑disease product and for BioNTech as it re‑targets its portfolio toward higher‑value oncology assets.